AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
alcaftadine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| histamine-H1 receptor antagonists, tricyclic compounds | 4165 | 147084-10-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Alcaftadine is an H1 histamine receptor antagonist and inhibitor of the release of histamine from mast cells. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,CAMK2D,EGFR,EIF2AK3,GRK2,ITK,MAPK10,MET,PDK1,PDK2,PDK4,PRKDC | 12 | |||
| kinase-selectivity-class | AXL,CAMK2D,SIK2 | 3 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 28, 2010 | FDA | ALLERGAN |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ocular hyperaemia | 436.36 | 86.48 | 84 | 419 | 33714 | 90594230 |
| Eye irritation | 209.20 | 86.48 | 46 | 457 | 33932 | 90594012 |
| Scleral hyperaemia | 130.16 | 86.48 | 16 | 487 | 300 | 90627644 |
| Eye pruritus | 107.02 | 86.48 | 26 | 477 | 29001 | 90598943 |
| Eyelid oedema | 95.35 | 86.48 | 20 | 483 | 11514 | 90616430 |
| Eye swelling | 91.52 | 86.48 | 23 | 480 | 29363 | 90598581 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ocular hyperaemia | 343.94 | 101.99 | 66 | 341 | 39220 | 110549672 |
| Eye irritation | 187.61 | 101.99 | 39 | 368 | 33413 | 110555479 |
| Scleral hyperaemia | 136.24 | 101.99 | 16 | 391 | 311 | 110588581 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | S01GX11 | SENSORY ORGANS OPHTHALMOLOGICALS DECONGESTANTS AND ANTIALLERGICS Other antiallergics |
| FDA MoA | N0000000190 | Histamine H1 Receptor Antagonists |
| MeSH PA | D006633 | Histamine Antagonists |
| MeSH PA | D006634 | Histamine H1 Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018494 | Histamine Agents |
| FDA EPC | N0000175587 | Histamine-1 Receptor Antagonist |
| CHEBI has role | CHEBI:37955 | H<small><sub>1</sub></small>-receptor antagonist |
| CHEBI has role | CHEBI:50857 | anti-allergic agent |
Related Drugs by ATC class:
S01GX Other antiallergics 12 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Allergic conjunctivitis | indication | 473460002 | DOID:11204 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.27 | Basic |
| pKa2 | 2.99 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.25% | LASTACAFT | ABBVIE | N022134 | July 28, 2010 | OTC | SOLUTION/DROPS | OPHTHALMIC | 10617695 | March 19, 2027 | USE OF LASTACAFT TO TEMPORARY RELIEVE ITCHY EYES DUE TO POLLEN, RAGWEED, GRASS, ANIMAL HAIR AND DANDER |
| 0.25% | LASTACAFT | ABBVIE | N022134 | July 28, 2010 | OTC | SOLUTION/DROPS | OPHTHALMIC | 8664215 | Dec. 23, 2027 | USE OF LASTACAFT TO TEMPORARY RELIEVE ITCHY EYES DUE TO POLLEN, RAGWEED, GRASS, ANIMAL HAIR AND DANDER |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Histamine H1 receptor | GPCR | ANTAGONIST | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4030132 | VUID |
| N0000181719 | NUI |
| D06552 | KEGG_DRUG |
| 4030132 | VANDF |
| C2348241 | UMLSCUI |
| CHEBI:71023 | CHEBI |
| CHEMBL1201747 | ChEMBL_ID |
| DB06766 | DRUGBANK_ID |
| C557708 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7587 | IUPHAR_LIGAND_ID |
| 8707 | INN_ID |
| 7Z8O94ECSX | UNII |
| 19371515 | PUBCHEM_CID |
| 1000082 | RXNORM |
| 175605 | MMSL |
| 27322 | MMSL |
| 013612 | NDDF |
| 447208001 | SNOMEDCT_US |
| 447209009 | SNOMEDCT_US |
| 7Z8O94ECSX | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| LASTACAFT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-4290 | SOLUTION/ DROPS | 2.50 mg | OPHTHALMIC | NDA | 24 sections |
| LASTACAFT | HUMAN OTC DRUG LABEL | 1 | 0023-4291 | SOLUTION/ DROPS | 2.50 mg | OPHTHALMIC | NDA | 13 sections |
| LASTACAFT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-288 | SOLUTION/ DROPS | 2.50 mg | OPHTHALMIC | NDA | 23 sections |
| LASTACAFT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6294 | SOLUTION/ DROPS | 2.50 mg | OPHTHALMIC | NDA | 23 sections |
| Alcaftadine | Human OTC Drug Label | 1 | 58602-605 | SOLUTION/ DROPS | 2.50 mg | OPHTHALMIC | ANDA | 13 sections |
| alcaftadine | Human OTC Drug Label | 1 | 62332-147 | SOLUTION/ DROPS | 2.50 mg | OPHTHALMIC | ANDA | 12 sections |
| Alcaftadine | Human OTC Drug Label | 1 | 68083-649 | SOLUTION/ DROPS | 2.50 mg | OPHTHALMIC | ANDA | 12 sections |